EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseOpen Access · CC BY 4.0

Time to Meaningful Clinical Response Across Approved and Emerging Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Network Meta-Analysis

Sarayu Balachandar iD, Dylan R Clapp iD, Alan B Fleischer iD

Journal of Clinical Medicine · 14.06.2026 · 15 (12) · 4622

DOI: 10.3390/jcm15124622 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Journal of Clinical Medicine, online erschienen am 14.06.2026. Verfasst von Sarayu Balachandar und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Several novel biologics and small-molecule therapies have emerged for the treatment of antihistamine-refractory chronic spontaneous urticaria (CSU), yet no study has directly compared their speed of response. This study aims to provide indirect evidence on the relative time to meaningful clinical response across approved and investigational therapies using a Bayesian network meta-analysis.

Methods

Phase 2 and phase 3 randomized controlled trials reporting UAS7 scores in a graphical format for antihistamine-refractory CSU were included. The primary outcome was the mean time in weeks to minimal clinically important difference (MCID), defined as a UAS7 reduction of 10 points. Data were extracted using WebPlotDigitizer (v4.7) and analyzed via Bayesian random-effects network meta-analysis in MetaInsight (v6.4.0), with placebo as the reference node.

Results

All drugs except rilzabrutinib 400 mg daily demonstrated faster mean time to MCID than placebo. Fenebrutinib had the fastest mean time to MCID (0.67–0.76 weeks), and tezepelumab the slowest (5.41–5.65 weeks). Only omalizumab 300 mg every 4 weeks, dupilumab 300 mg every 2 weeks, and ligelizumab 72 mg and 120 mg every 4 weeks achieved statistically significant reductions compared with placebo. All treatments had wide credible intervals reflecting limited direct comparisons.

Conclusions

This is the first network meta-analysis comparing time to meaningful symptom control across therapies for antihistamine-refractory CSU. Omalizumab, dupilumab, and ligelizumab demonstrated statistically significant reductions in time to MCID compared with placebo. Head-to-head trials with standardized outcome reporting would enable more definitive comparative conclusions.

Schlagwörter

Stichwörter der Autor:innen

UAS7chronic spontaneous urticarianetwork meta-analysisurticaria activity score

Autor:innen und Institutionen

  • University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
  • Department of Dermatology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.

ORCID-Profile: Sarayu Balachandar, Dylan R Clapp, Alan B Fleischer

Zitieren

APA

Balachandar, S., Clapp, D. R., & Fleischer, A. B. (2026). Time to Meaningful Clinical Response Across Approved and Emerging Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Network Meta-Analysis. Journal of Clinical Medicine, 15(12), 4622. https://doi.org/10.3390/jcm15124622

Vancouver

Balachandar S, Clapp DR, Fleischer AB. Time to Meaningful Clinical Response Across Approved and Emerging Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Network Meta-Analysis. Journal of Clinical Medicine. 2026;15(12):4622. doi:10.3390/jcm15124622

BibTeX
@article{Balachandar2026,
  author = {Balachandar, Sarayu and Clapp, Dylan R and Fleischer, Alan B},
  title = {Time to Meaningful Clinical Response Across Approved and Emerging Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Network Meta-Analysis},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {12},
  pages = {4622},
  doi = {10.3390/jcm15124622}
}
Kostenlos starten →